The Researched Medicines Industry Association of New Zealand (RMI) is the professional and trade organisation representing companies engaged in the research, development, manufacture and marketing of prescription medicines.

Membership of the RMI is voluntary. The governing body of the RMI is its Board of Directors which consists of eight members elected annually in March from the chief executive officers of member companies.

Membership of the RMI is voluntary. The governing body of the RMI is its Board of Directors which consists of eight members elected annually from the chief executive officers of member companies.

The RMI works to:

1. Demonstrate the value of medicines, within the context of total health care

2. Ensure access for all New Zealanders and their medical advisors to new medicines

3. Encourage and support continuing advancement in medical science and its application in health

4. Ensure the industry, through the RMI, is recognised by the health sector and the community generally as a key partner in maintaining the good health of all New Zealanders.

Board of Directors 2010/11

Lex Henry, non-executive Chairman
Alan Carter, Vice Chairman, and Country Manager, sanofi-aventis
Nick Leach, NZ Director, Abbott Laboratories
Darcy Downey, Managing Director, Boehringer Ingelheim
Geoff McDonald, General Manager, GlaxoSmithKline
Chris Hourigan, Associate Director, Janssen-Cilag
Sean Evans, General Manager, Novartis
Frances Benge,Country Lead, Pfizer NZ Limited
Stuart Knight, Managing Director, Roche Products (NZ) Limited

Secretariat

Chief Executive Officer - Denise Wood
Scientific and Technical Manager - Kevin Sheehy
Communications Manager - Christine Ross
Executive Assistant - Michelle Gibbs